Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. Academic Article uri icon

Overview

abstract

  • Fascin protein is the main actin-bundling protein in filopodia and invadopodia, which are critical for tumor cell migration, invasion, and metastasis. Small-molecule fascin inhibitors block tumor invasion and metastasis and increase the overall survival of tumor-bearing mice. Here, we report a finding that fascin blockade additionally reinvigorates anti-tumor immune response in syngeneic mouse models of various cancers. Fascin protein levels are increased in conventional dendritic cells (cDCs) in the tumor microenvironment. Mechanistically, fascin inhibitor NP-G2-044 increases the number of intratumoral-activated cDCs and enhances the antigen uptake by cDCs. Furthermore, together with PD-1 blocking antibody, NP-G2-044 markedly increases the number of activated CD8+ T cells in the otherwise anti-PD-1 refractory tumors. Reduction of fascin levels in cDCs, but not fascin gene knockout in tumor cells, mimics the anti-tumor immune effect of NP-G2-044. These data demonstrate that fascin inhibitor NP-G2-044 simultaneously limits tumor metastasis and reinvigorates anti-tumor immune responses.

publication date

  • April 6, 2021

Research

keywords

  • Carrier Proteins
  • Dendritic Cells
  • Immunity
  • Microfilament Proteins
  • Neoplasms

Identity

PubMed Central ID

  • PMC8050791

Scopus Document Identifier

  • 85103795258

Digital Object Identifier (DOI)

  • 10.1016/j.celrep.2021.108948

PubMed ID

  • 33826900

Additional Document Info

volume

  • 35

issue

  • 1